BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

70.73 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

What BridgeBio Pharma (BBIO) Said on Its Q3 Earnings Call ↗

October 29, 2026

BridgeBio Pharma (NASDAQ:BBIO) reported third-quarter revenue growth driven by sales of ATTR cardiomyopathy treatment Attruby and a one-time milestone tied to European partner Bayer’s commercialization...

Via MarketBeat

Topics Earnings

BridgeBio Pharma (NASDAQ:BBIO) Q3 Beat Masks Milestone-Reliant Revenue Ahead of Key PDUFA Catalysts ↗

October 29, 2026

Via Chartmill

BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status ↗

September 26, 2026

BridgeBio Pharma (NASDAQ:BBIO) expects 2027 to be a transformative year as it expands from one commercial product to four globally launched therapies, President and CFO Thomas Trimarchi said during a...

Via MarketBeat

BridgeBio (BBIO) Q2 2026 Earnings Call Transcript ↗

August 19, 2026

Attruby revenue surged to $222.4 million as three pipeline programs entered regulatory review.

Via The Motley Fool

Topics Earnings

BridgeBio Pharma (NASDAQ:BBIO) Flashes Perfect Technical Score and Tight Breakout Setup ↗

August 11, 2026

Via Chartmill

BridgeBio Pharma (NASDAQ:BBIO) Q1 2026 Revenue Beat Driven by Attruby Sales Surge, Shares Jump ↗

May 07, 2026

Via Chartmill

BridgeBio Pharma Inc (NASDAQ:BBIO) Posts Q4 Revenue Beat on Heart Drug Surge, Eyes Multiple 2026 NDA Submissions ↗

February 24, 2026

Via Chartmill

Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗

August 16, 2026

Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think.

Via The Motley Fool

BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher. ↗

August 14, 2026

The company clearly has a winner on its hands with the recently approved Attruby.

Via The Motley Fool

BridgeBio Pharma Q2 Earnings Call Highlights ↗

August 10, 2026

BridgeBio Pharma (NASDAQ:BBIO) reported continued growth for its ATTR cardiomyopathy treatment Attruby in the second quarter of 2026, while advancing three late-stage programs into regulatory review...

Via MarketBeat

Topics Earnings

1 Top Wall Street Analyst Thinks This Stock Could Soar 95% Over the Next 12 Months. Here's Why I Agree. ↗

August 02, 2026

Rapid commercial momentum could justify Wall Street's bullish outlook.

Via The Motley Fool

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions ↗

July 13, 2026

Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.

Via MarketBeat

There are notable gap-ups and gap-downs in today's session. ↗

July 09, 2026

Via Chartmill

Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right. ↗

July 02, 2026

Analysts have given Alnylam Pharmaceuticals an average price target of $436.

Via The Motley Fool

BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches ↗

May 13, 2026

BridgeBio Pharma (NASDAQ:BBIO) executives used a BofA healthcare conference appearance in Las Vegas to reiterate confidence in the commercial trajectory of Attruby and outline expectations for three...

Via MarketBeat

BridgeBio (BBIO) Q1 2026 Earnings Transcript ↗

May 08, 2026

BridgeBio (BBIO) Q1 2026 Earnings Transcript

Via The Motley Fool

BridgeBio (BBIO) Q2 2025 Earnings Transcript ↗

April 28, 2026

BridgeBio (BBIO) Q2 2025 Earnings Transcript

Via The Motley Fool

Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity

April 13, 2026

In a move that signals a transformative shift from a clinical-stage biotech to a commercial-market leader, Ascendis Pharma (NASDAQ: ASND) officially launched its third major product, YUVIWEL...

Via MarketMinute

Topics Economy

BridgeBio Pharma Inc (NASDAQ:BBIO) Shows High Technical and Setup Ratings Ahead of Potential Breakout ↗

April 11, 2026

BridgeBio Pharma (BBIO) shows a strong technical uptrend with a high-quality consolidation pattern, signaling a potential breakout opportunity for traders.

Via Chartmill

BridgeBio (BBIO) Q4 2025 Earnings Call Transcript ↗

February 24, 2026

BridgeBio (BBIO) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites ↗

February 17, 2026

Optimism also grew around FDA momentum for its palmoplantar pustulosis drug ahead of MoonLake’s Feb. 23 investor day.

Via Stocktwits

Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗

February 17, 2026

Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma.

Via The Motley Fool

Topics Regulatory Compliance

Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough ↗

February 17, 2026

Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions.

Via The Motley Fool

Topics Regulatory Compliance

Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge ↗

February 17, 2026

This clinical-stage biotech develops therapies for NASH and obesity, advancing a diverse pipeline of small-molecule drug candidates.

Via The Motley Fool

Topics Regulatory Compliance

Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance

February 12, 2026

As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. Known as...

Via Finterra

Topics Economy Intellectual Property

BBIO Stock Surges 17% Pre-Market Today – What’s Fueling The Rally? ↗

February 12, 2026

The company reported positive results from its PROPEL 3 study of its experimental oral therapy, infigratinib, in children with achondroplasia, a genetic form of dwarfism.

Via Stocktwits

The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate

February 02, 2026

The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative...

Via MarketMinute

Topics ETFs Government Initial Public Offering

BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance

January 02, 2026

In a move that has sent shockwaves through the biotechnology sector, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced on December 19, 2025, that it has entered into a definitive agreement to...

Via MarketMinute

Topics Economy Intellectual Property

The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500

January 02, 2026

As the calendar turns to 2026, Alnylam Pharmaceuticals (Nasdaq: ALNY) stands at the threshold of a new era. Once a speculative pioneer in the arcane world of RNA interference (RNAi), the...

Via PredictStreet

Topics Economy Intellectual Property Stocks

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗

December 22, 2025

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?

Via The Motley Fool

Topics Regulatory Compliance

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.